SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals, Inc. - MRNS

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Marinus Pharmaceuticals and its officers or directors [1] Company Developments - On April 15, 2024, Marinus announced that its pivotal Phase 3 RAISE trial for intravenous ganaxolone did not meet early stopping criteria and that the company would implement cost reduction activities to extend its cash runway beyond Q4 2024 [3] - Following this announcement, Marinus's stock price dropped by $6.32, or 84.04%, closing at $1.20 per share on April 16, 2024 [3] - On May 8, 2024, Marinus announced the cessation of the Phase 3 Raise II trial in refractory status epilepticus (RSE) and stated that future development in RSE would be assessed after reviewing the RAISE topline data [4] - This announcement led to a further decline in Marinus's stock price by $0.14, or 8.91%, closing at $1.43 per share on May 8, 2024 [4]